Cutting-Edge Transporter Research Forum in Tokyo

－ Exploring Transporters Together: Global Voices, Shared Visions －

October 27-28, Tokyo, Japan

Program

Cutting-Edge Transporter Research Forum in Tokyo

The program features plenary and keynote lectures, along with presentations from leading experts in academia and industry, covering cutting-edge topics in transporter science, PBPK modeling, and drug-drug interactions.

A detailed program is available as a PDF.

Download Full Program

Day 1 - October 27, 2026

09:15

Opening Remarks

Symposium 1: Frontiers in Transporter Science:
From Fundamental Discoveries to Future Directions

09:35

Plenary Lecture
Aleksandra Galetin (University of Manchester)
Impact of Disease‑Driven Alterations in Drug Transporters on Clinical Outcomes and DDIs

10:25

Keynote Lecture
Yuichi Sugiyama (Professor Emeritus, The University of Tokyo; GenoMembrane Co., Ltd.)
Critical Factors for Translating In Vitro Data into PBPK Predictions of Highly Protein-Bound Anionic Drugs

11:05

Ikumi Tamai (Emeritus Professor, Kanazawa University)
Recent Advances in the Pathophysiology of Uric Acid and Selective URAT1 Inhibitors

11:35

Lunch Break

12:35

Keynote Lecture
Kazuya Maeda (Kitasato University School of Pharmacy)
Prediction of the Properties of Intestinal Drug Transport and Metabolism with the Use of Human Crypt-derived Differentiated Intestinal Epithelial Cells

13:15

Tatsuki Mochizuki (Chugai Pharmaceutical Co., Ltd.)
Challenges in Overcoming the in Vitro-in Vivo Discrepancy in OATP Inhibition

13:45

Saki Izumi (Eisai Co., Ltd.)
Analysis of OATP1B Inhibition by Cyclosporin A in Humans Incorporating a Trans-Inhibition Mechanism: Application of Middle Approach Using CGNM

14:15

Break

14:30

Yan Zhang (Nuvation Bio)
Transporters in ADMET: Key Drivers in Clinical Pharmacokinetics and Drug Development

15:00

Wooin Lee (College of Pharmacy, Seoul National University)
Transporters and Stereoselective Disposition of Warfarin in Humans

15:30

Yoshiyuki Shirasaka (Showa Pharmaceutical University)
Risk Analysis of Drug-Drug Interactions Considering Gastrointestinal Disposition of P-gp Substrates/Inhibitors

16:00

Keynote Lecture
Kousei Ito (Graduate School of Pharmaceutical Sciences, Chiba University)

Bile Acid Transporters in Drug-Induced Liver Injury: Contributions to Hepatocellular Death and Inflammation

16:40

General Discussion

17:40

Banquet

Day 2 - October 28, 2026

Symposium 2: Transporter-Mediated DDIs:
Endogenous Biomarkers and Bridging In Vitro–In Vivo Gaps

09:00

Keynote Lecture
Hiroyuki Kusuhara (Graduate School of Pharamaceutical Sciences, The University of Tokyo)
Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1

09:40

Xiaoyan Chu (Merck & Co.)
Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method

10:10

Ryota Kikuchi (AbbVie)
Recent Advances in Coproporphyrin-I as a Biomarker for OATP1B-Mediated Drug–Drug Interactions

10:40

Emi Kimoto (Pfizer Inc.)
Use of Biomarker-Informed Approach to Support Drug Interaction Risk Assessment

11:10

Shinji Nakayama (Tanabe Pharma Corporation)
PBPK Modeling for Investigating the Effect of Simeprevir on Concomitant Drugs and an Endogenous Biomarkers (CP-I and Bilirubin) of OATP1B

11:40

Zhubing Hao (Research Institute for Liver Diseases (Shanghai) Co., Ltd.
PBPK Modeling Analyses of Letermovir, an Antiviral for Cytomegalovirus Prophylaxis: Middle-Out Approaches to OATP1B-Mediated Nonlinear Pharmacokinetics and Drug-Drug Interactions Using CGNM

12:10

Tadayuki Takashima (Asahi Kasei Pharma Corporation)
Nonlinear Pharmacokinetics of Endothelin Receptor Antagonists, Bosentan and Tezosentan, Involve Saturable Albumin-Mediated Hepatic Uptake via OATP1B: Top-down and Middle-out Analysis Using CGNM Method Considering In Vitro Human Hepatic Uptake Data

12:40

Lunch Break

Symposium 3: Role of Transporters in Special Populations: Implications for Clearance and Drug–Drug Interactions

13:40

Plenary Lecture
Bhagwat Prasad (Cincinnati Children's Hospital Medical Center
Opportunities and Challenges in Implementing Drug Transporter Biomarkers for DDI Assessment and Prediction of Pharmacokinetic Variability

14:30

Toshiaki Tsuchitani (Keio University Faculty of Pharmacy)
Characterizing Pharmacokinetics of Apixaban and Edoxaban Through Physiologically-Based Pharmacokinetic Modeling: Importance of Renal Clearance, Biliary Excretion, and Enterohepatic Circulation in Humans

15:00

Ryuta Asaumi (Astellas Pharma Inc.)
Predicting Pharmacokinetics in Cirrhosis: Key Determinants and Their Application to Static and Dynamic (PBPK) Models
— Integrating the Intact Hepatocyte and Sick Hepatocyte Hypotheses —

15:30

Masanobu Sato (Nippon Boehringer Ingelheim Co., Ltd.)
Can the Frequency of Hypoglycemic Events Induced by the Antidiabetic Drug Repaglinide Be Predicted by a PBPK Modeling Approach Considering Drug Interactions and Genetic Variants of OATP1B1? A Comparison with Real-World Data

16:00

Keynote Lecture
Sumito Ito (GenoMembrane Co., Ltd.)
Utility of In Vitro Cell-Based Systems for Translational Transporter Research: How should the assumptions underlying the application of the REF method be handled?

16:40

General Discussion

For inquiries, please use the contact form.

Contact

Cutting-Edge Transporter Research Forum in Tokyo

－ Exploring Transporters Together: Global Voices, Shared Visions －

October 27-28, Tokyo, Japan

Program

Day 1 - October 27, 2026

09:15

Opening Remarks

Symposium 1: Frontiers in Transporter Science: From Fundamental Discoveries to Future Directions

09:35

Plenary Lecture Aleksandra Galetin (University of Manchester) Impact of Disease‑Driven Alterations in Drug Transporters on Clinical Outcomes and DDIs

10:25

Keynote Lecture Yuichi Sugiyama (Professor Emeritus, The University of Tokyo; GenoMembrane Co., Ltd.) Critical Factors for Translating In Vitro Data into PBPK Predictions of Highly Protein-Bound Anionic Drugs

11:05

Ikumi Tamai (Emeritus Professor, Kanazawa University) Recent Advances in the Pathophysiology of Uric Acid and Selective URAT1 Inhibitors

11:35

Lunch Break

12:35

Keynote Lecture Kazuya Maeda (Kitasato University School of Pharmacy) Prediction of the Properties of Intestinal Drug Transport and Metabolism with the Use of Human Crypt-derived Differentiated Intestinal Epithelial Cells

13:15

Tatsuki Mochizuki (Chugai Pharmaceutical Co., Ltd.) Challenges in Overcoming the in Vitro-in Vivo Discrepancy in OATP Inhibition

13:45

Saki Izumi (Eisai Co., Ltd.) Analysis of OATP1B Inhibition by Cyclosporin A in Humans Incorporating a Trans-Inhibition Mechanism: Application of Middle Approach Using CGNM

14:15

Break

14:30

Yan Zhang (Nuvation Bio) Transporters in ADMET: Key Drivers in Clinical Pharmacokinetics and Drug Development

15:00

Wooin Lee (College of Pharmacy, Seoul National University) Transporters and Stereoselective Disposition of Warfarin in Humans

15:30

Yoshiyuki Shirasaka (Showa Pharmaceutical University) Risk Analysis of Drug-Drug Interactions Considering Gastrointestinal Disposition of P-gp Substrates/Inhibitors

16:00

Keynote Lecture Kousei Ito (Graduate School of Pharmaceutical Sciences, Chiba University)

Bile Acid Transporters in Drug-Induced Liver Injury: Contributions to Hepatocellular Death and Inflammation

16:40

General Discussion

17:40

Banquet

Contact

Symposium 1: Frontiers in Transporter Science:
From Fundamental Discoveries to Future Directions

Plenary Lecture
Aleksandra Galetin (University of Manchester)
Impact of Disease‑Driven Alterations in Drug Transporters on Clinical Outcomes and DDIs

Keynote Lecture
Yuichi Sugiyama (Professor Emeritus, The University of Tokyo; GenoMembrane Co., Ltd.)
Critical Factors for Translating In Vitro Data into PBPK Predictions of Highly Protein-Bound Anionic Drugs

Ikumi Tamai (Emeritus Professor, Kanazawa University)
Recent Advances in the Pathophysiology of Uric Acid and Selective URAT1 Inhibitors

Keynote Lecture
Kazuya Maeda (Kitasato University School of Pharmacy)
Prediction of the Properties of Intestinal Drug Transport and Metabolism with the Use of Human Crypt-derived Differentiated Intestinal Epithelial Cells

Tatsuki Mochizuki (Chugai Pharmaceutical Co., Ltd.)
Challenges in Overcoming the in Vitro-in Vivo Discrepancy in OATP Inhibition

Saki Izumi (Eisai Co., Ltd.)
Analysis of OATP1B Inhibition by Cyclosporin A in Humans Incorporating a Trans-Inhibition Mechanism: Application of Middle Approach Using CGNM

Yan Zhang (Nuvation Bio)
Transporters in ADMET: Key Drivers in Clinical Pharmacokinetics and Drug Development

Wooin Lee (College of Pharmacy, Seoul National University)
Transporters and Stereoselective Disposition of Warfarin in Humans

Yoshiyuki Shirasaka (Showa Pharmaceutical University)
Risk Analysis of Drug-Drug Interactions Considering Gastrointestinal Disposition of P-gp Substrates/Inhibitors

Keynote Lecture
Kousei Ito (Graduate School of Pharmaceutical Sciences, Chiba University)